BACKGROUND: This study investigated the relationship between depressive symptom response during tryptophan depletion and future depressive episodes. METHODS:Twelve subjects with prior major depressive episodes in remission and medication-free for > or =3 months (patients), and 12 matched healthy (control) subjects received twotryptophan depletion tests 1 week apart. During follow-up the Hamilton Depression Rating Scale was administered weekly for 1 month, monthly for 3 months, and once at 6 and 12 months. RESULTS: With results from both tests, tryptophan depletion has a sensitivity of 78%, specificity of 80%, positive predictive value of 70%, and negative predictive value of 86% to identify future depressive episodes. Survival analysis shows that mood response to tryptophan depletion reliably predicts major depressive episodes during the follow-up year (r =.2725, p =.014). CONCLUSIONS: Tryptophan depletion may be clinically useful in identifying individuals at risk for future major depressive episodes.
RCT Entities:
BACKGROUND: This study investigated the relationship between depressive symptom response during tryptophan depletion and future depressive episodes. METHODS: Twelve subjects with prior major depressive episodes in remission and medication-free for > or =3 months (patients), and 12 matched healthy (control) subjects received two tryptophan depletion tests 1 week apart. During follow-up the Hamilton Depression Rating Scale was administered weekly for 1 month, monthly for 3 months, and once at 6 and 12 months. RESULTS: With results from both tests, tryptophan depletion has a sensitivity of 78%, specificity of 80%, positive predictive value of 70%, and negative predictive value of 86% to identify future depressive episodes. Survival analysis shows that mood response to tryptophan depletion reliably predicts major depressive episodes during the follow-up year (r =.2725, p =.014). CONCLUSIONS:Tryptophan depletion may be clinically useful in identifying individuals at risk for future major depressive episodes.
Authors: Francisco A Moreno; Damian Parkinson; Craig Palmer; Wm Lesley Castro; John Misiaszek; Aram El Khoury; Aleksander A Mathé; Ron Wright; Pedro L Delgado Journal: Eur Neuropsychopharmacol Date: 2010-01 Impact factor: 4.600
Authors: John J B Allen; Katherine M McKnight; Francisco A Moreno; Heath A Demaree; Pedro L Delgado Journal: J Affect Disord Date: 2008-09-18 Impact factor: 4.839
Authors: Andrew A Fingelkurts; Alexander A Fingelkurts; Heikki Rytsälä; Kirsi Suominen; Erkki Isometsä; Seppo Kähkönen Journal: Hum Brain Mapp Date: 2007-03 Impact factor: 5.038
Authors: Uttam K Raheja; Dietmar Fuchs; Ina Giegling; Lisa A Brenner; Sergio F Rovner; Iqra Mohyuddin; Daniel Weghuber; Harald Mangge; Dan Rujescu; Teodor T Postolache Journal: Pteridines Date: 2015-06 Impact factor: 0.581
Authors: Debra A Scrandis; Patricia Langenberg; Leonardo H Tonelli; Tehmina M Sheikh; Anita C Manogura; Laura A Alberico; Tracey Hermanstyne; Dietmar Fuchs; Hugh Mighty; Jeffrey D Hasday; Kalina Boteva; Teodor T Postolache Journal: Int J Child Health Hum Dev Date: 2008-08
Authors: J Douglas Bremner; Meena Vythilingam; Chin K Ng; Eric Vermetten; Ahsan Nazeer; Dan A Oren; Robert M Berman; Dennis S Charney Journal: JAMA Date: 2003-06-18 Impact factor: 56.272